Close Close
Sign In
Newsletters
Popular Financial Topics Discover relevant content from across the suite of ALM legal publications From the Industry More content from ThinkAdvisor and select sponsors Investment Advisor Issue Gallery Read digital editions of Investment Advisor Magazine Tax Facts Get clear, current, and reliable answers to pressing tax questions
Luminaries Awards
Podcast Center Video Center Webcasts Resource Center Events
About ThinkAdvisor Contact Us Advertise With Us Asset & Logo Licensing Sitemap Terms of Service Privacy Policy Copyright © 2024 ALM Global, LLC. All Rights Reserved.
ThinkAdvisor

Retirement Planning > Saving for Retirement

Rx Manager Seeks To Buy Caremark

By Staff Writer

X
Your article was successfully shared with the contacts you provided.

Express Scripts Inc. bid to acquire a competing pharmacy benefits manager, challenging a pharmacy chain’s offer to buy the same company.

Express Scripts, St. Louis, proposed to acquire all outstanding shares of Caremark Rx Inc., Birmingham, Ala., for $29.25 in cash and about 0.4 shares of its own stock for each Caremark share.

Its bid topped a competing offer by the drugstore chain CVS Corp., Woonsocket, R.I. Based on Express Scripts’ closing stock price on Friday, December 15th, the pharmacy benefits manager’s offer has a total value of $26 billion.

Express Scripts says its offer represents a 15% premium over the all-stock purchase price proposed by CVS Corporation.

If the deal is completed, Caremark stockholders would own around 57% of the combined company, compared to 43% held by Express Scripts stockholders, according to the bid announcement. Express Scripts expects the proposed deal would be completed in the third quarter of 2007.

The transaction would create annual cost savings of around $500 million for the combined firm, Express Scripts estimates.

NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.